On May 12, 2015, BG Medicine, Inc. (“company”) entered into a securities purchase agreement with the company's principal stockholders, Applied Genomic Technology Capital Fund, L.P., AGTC Advisors Fund, L.P. and Flagship Ventures Fund 2007, L.P. (the “Purchasers”), which are affiliates of company's directors, Noubar B. Afeyan, Ph.D. and Harry W. Wilcox. Pursuant to the terms and subject to the conditions contained in the purchase agreement, the company issued and sold to the Purchasers secured convertible promissory notes in aggregate principal amount of $500,000. On May 12, 2015, Stéphane Bancel, who is affiliated with Flagship Ventures, resigned from the Board of the company, effective as of that time.

Also, effective as of that time, the Board appointed Harry W. Wilcox, also an affiliate of Flagship Ventures, to fill the vacancy created by Mr. Bancel's resignation. Subject to SEC and NASDAQ corporate governance rules, Mr. Wilcox will serve on the company's Nominating and Governance Committee and its Compensation Committee. It is anticipated that following the Second Closing of the Financing and the issuance of the Series A Preferred Stock, Mr. Wilcox will remain on the Board and his seat will transition into that of the Preferred Elected Director.

Harry W. Wilcox has served on the Board of Directors since May 2015. Mr. Wilcox has been Chief Operating Officer and General Partner of Flagship Ventures since 2013. From 2006 to 2013, he was Chief Financial Officer and Partner of Flagship Ventures.

Mr. Wilcox currently serves as a director of T2 Biosystems, Inc.